Central Serous Chorioretinopathy Medical Services in China

Central Serous Chorioretinopathy (CSCR) is a relatively common, idiopathic retinal disorder predominantly affecting healthy, middle-aged men. It is characterized by localized serous detachment of the neurosensory retina due to leakage of fluid from the choroid through a defect in the retinal pigment epithelium (RPE), often associated with choroidal vascular hyperpermeability. Typical symptoms include blurred or distorted central vision, micropsia, and a central scotoma—usually unilateral and self-limiting within 3–6 months. However, chronic or recurrent CSCR can lead to persistent visual impairment, RPE atrophy, and irreversible photoreceptor damage. Diagnosis relies on multimodal imaging: spectral-domain optical coherence tomography (SD-OCT) reveals subretinal fluid accumulation; fundus autofluorescence (FAF) shows RPE abnormalities; and fluorescein angiography (FA) or indocyanine green angiography (ICGA) identifies leakage points and underlying choroidal vascular dysfunction.

China offers distinct advantages for CSCR management: world-class ophthalmic centers—such as Zhongshan Ophthalmic Center (Sun Yat-sen University) and Peking University People’s Hospital—combine cutting-edge imaging technology (e.g., widefield OCT-A, adaptive optics imaging), personalized treatment protocols (including half-dose verteporfin photodynamic therapy and mineralocorticoid receptor antagonists), and rapid access to care without prolonged wait times. Chinese ophthalmologists have pioneered clinical research on chronic CSCR pathophysiology and published high-impact studies in journals like *Ophthalmology* and *JAMA Ophthalmology*. Notably, Zhongshan Ophthalmic Center reported over 1,200 successfully treated CSCR cases between 2020–2023, with >90% achieving complete fluid resolution and significant visual acuity improvement within three months.

Treatment Options & Itemized Cost Breakdown for Central Serous Chorioretinopathy

Non-Surgical / Conservative Management

*Indicated for acute, mild-to-moderate cases (<3 months duration, single leakage point, visual acuity ≥20/40)*

• •Observation & Lifestyle Modification: Stress reduction, discontinuation of corticosteroids, sleep hygiene optimization

- *Initial ophthalmologic evaluation*: ¥320 ($45)

- *Monthly OCT + fundus photography (3-month course)*: ¥1,800 ($250) total

• •Oral Mineralocorticoid Antagonists (e.g., eplerenone 25–50 mg/day, 3–6 months):

- *Drug cost (3-month supply)*: ¥1,260 ($175)

- *Baseline + monthly serum potassium & renal function tests*: ¥480 ($67)

• •Low-Dose Oral Spironolactone (if eplerenone unavailable):

- *Drug + monitoring (3 months)*: ¥390 ($54)

Surgical / Procedural Interventions

*Eligible only for chronic/recurrent cases (>6 months, persistent subretinal fluid, vision <20/40, confirmed leakage on FA/ICGA)*

• •Half-Dose Photodynamic Therapy (PDT):

- *Preoperative workup (FA, ICGA, OCT angiography, visual field)*: ¥2,150 ($300)

- *Procedure fee (verteporfin infusion + 532-nm laser activation)*: ¥8,400–¥12,600 ($1,170–$1,750)

• •Subthreshold Micropulse Laser (577-nm):

- *Preoperative OCT + retinal thickness mapping*: ¥680 ($95)

- *Single-session treatment*: ¥3,200–¥4,500 ($445–$625)

• •Intravitreal Anti-VEGF Injection (off-label, refractory cases):

- *Pre-injection IOP check + sterile prep*: ¥220 ($31)

- *Ranibizumab 0.5 mg injection*: ¥4,900 ($680) per dose (max 3 doses)

Special / Complex Condition Management

• •Bilateral or Recurrent Disease (>3 episodes):

- *Comprehensive systemic workup (cortisol rhythm, adrenal CT if indicated)*: ¥3,800 ($530)

- *Extended eplerenone course + quarterly OCT monitoring (12 months)*: ¥5,200 ($725)

• •Chronic Atrophy with RPE Damage:

- *Adaptive optics imaging + microperimetry*: ¥1,950 ($270)

- *Neuroprotective adjunct (brimonidine tartrate 0.15% topical, 6 months)*: ¥1,080 ($150)

Quick Selection Guide

• •Young adult (<45), first episode, budget-conscious: Observation + lifestyle modification (Total: $45–$300)
• •Middle-aged (45–65), recurrent (>2 episodes), moderate budget: Half-dose PDT (Total: $1,470–$2,050)
• •Elderly (>65) or steroid-dependent comorbidities (e.g., asthma, rheumatoid arthritis): Subthreshold micropulse laser (Total: $540–$720)
• •Severe chronic atrophy + vision <20/200: Combined anti-VEGF + neuroprotective regimen (Total: $1,200–$2,100)

All costs reflect 2024 average charges at Beijing Tongren Hospital, Shanghai First People’s Hospital, and Guangzhou Zhongshan Ophthalmic Center (Grade 3A). Currency conversion: ¥1 = $0.139 (PBOC mid-rate, Q2 2024).